Compare AG & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | KYMR |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.6B |
| IPO Year | 2004 | 2020 |
| Metric | AG | KYMR |
|---|---|---|
| Price | $16.96 | $114.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 26 |
| Target Price | $21.92 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 11.7M | 1.1M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $24.41 | $10.61 |
| Revenue Next Year | $10.68 | $8.17 |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.74 | $36.88 |
| 52 Week High | $32.00 | $130.05 |
| Indicator | AG | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 74.43 |
| Support Level | $15.58 | $72.91 |
| Resistance Level | $17.37 | N/A |
| Average True Range (ATR) | 0.91 | 7.53 |
| MACD | -0.00 | 3.09 |
| Stochastic Oscillator | 32.23 | 71.86 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.